Aurobindo Pharma USA is continuously striving to achieve product differentiation, specifically through formulation development and novel delivery methods of complex products. Numerous delivery methods are being developed in drug product including:

oral iconOral

  • Work on complex oral dosage forms including Osmotically Controlled Release Systems (OROS) based dosage, solutions and suspension and Hot Melt Extrusion (HME)
  • High potency compounds including potent compound suites (RD & Commercial) that control the rate at which an active ingredient is released
  • Develop and manufacture complex dosage forms using controlled drug substances (DEA schedule 1-4) to enable Abuse Deterrent Formulations (ADF) and REMS program drugs

icon-injectionInjectables

  • Working on complex injectable products in the field of sustained drug delivery including depot formulation, suspensions and polymer based products
  • For more information please visit, AuroMedics

Specialty Products

Aurobindo has built a new 40,000 sq. ft. state-of-the-art R&D and pilot plant facility in Durham, North Carolina. Further, build-out of a cGMP manufacturing facility for commercialization of specialty products on the same site has commenced. The new R&D labs site will house over 50 scientists, including highly experienced pMDI aerosol, topical and transdermal R&D teams, with associated analytical and testing labs.

icon-inhalerInhalation

  • Products under development include pMDIs, which comprise a drug formulation in an HFA (Hydro Fluro Alkanes) propellant system, filled under pressure in metal canisters with crimped metered dosing valves and actuators to guide the aerosol spray

icon-topicalTopical

  • Developments underway on a large portfolio of topical solutions, ointments, creams, gels and topical OTC products that act locally
  • For more information on OTC products, please visit Aurohealth 

icon-transdermalTransdermal

  • Development is underway for a matrix adhesive transdermal patch that acts systemically
  • Technology of the matrix adhesive patch enables the active ingredients to be formulated within the adhesive matrix, coated onto a backing liner and protected with a release liner that is removed prior to application

icon-nasalOther Research & Development Capabilities

  • A portfolio of products under development for nasal and ophthalmic delivery